103P - Evaluation of the conversion rate in Ki-67, estrogen receptor (ER), progesterone receptor (PR) and HER2 between primary breast cancer and relapse a...

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Biomarkers
Presenter Isabel Blancas López-Barajas
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors I. Blancas López-Barajas1, A. Muñoz2, M. Legerén3, F. Galvez1, R. González1, J.M. Jurado1, C.J. Rodriguez1, M. Delgado1, B. Gonzalez Astorga1, M. Yélamos1, S. Sequero3, V. Chacon3
  • 1Oncology, Hospital Clinico San Cecilio, 18012 - Granada/ES
  • 2Medicina, Facultad de Medicina. Universidad de Granada, Granada/ES
  • 3Oncology, Hospital Clinico San Cecilio, Granada/ES

Abstract

Background

The aims are to asses the different expression of ER, PR, HER2 and Ki-67 between primary tumor and the recurrence and theirs prognostic consequences.

Methods

Observational retrospective unicentric study of 45 breast cancer patients. We have two different populations: patients who have a local and complete resected relapse (LR) and patients with a metastatic biopsied disease (MD).The changes in ER, PR, HER2 and Ki-67 between the pathologist report of primary tumor and the biopsy of the relapse have been analyzed. We studied ER, PR, HER2 and Ki-67 determined in the relapse as prognostic factor for relapse free survival (RFS) and overall survival (OS) in the LR group, and for progression-free survival (PFS) and OS in MD group.

Results

The conversion rate of 34,8% for Ki-67 (p = 0,046), 20% for ER (p = 0,001), 20% for PR (p 

Conclusions

We observed a significative conversion rate in Ki-67, ER, PR and HER2 between primary breast cancer and relapse. We saw that ER- in the local relapse or metastasis, as well as a PR- in the metastasis were associated with a worse prognosis.

Clinical trial identification

Legal entity responsible for the study

Hospital Clinico San Cecilio Granada

Funding

Hospital Clinico San Cecilio Granada

Disclosure

All authors have declared no conflicts of interest.